Difference between revisions of "Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8468)"
Jump to navigation
Jump to search
(Created claim: Has Sectioning (P146): Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5) (Q8490), #quickstatements; #temporary_batch_1589931845914) |
(Created claim: Has Sectioning (P146): Bibliography (from DOI: 10.1038/s41392-020-0110-5) (Q10035), #quickstatements; #temporary_batch_1590236183485) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5) / rank | |||
| + | Normal rank | ||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: Competing interests (from DOI: 10.1038/s41392-020-0110-5) / rank | |||
| + | Normal rank | ||
| Property / Has Sectioning | |||
| + | |||
| Property / Has Sectioning: Bibliography (from DOI: 10.1038/s41392-020-0110-5) / rank | |||
| + | Normal rank | ||
Latest revision as of 12:16, 23 May 2020
Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
|
Publication: "Targeting cancer stem cell pathways for cancer therapy" published as Signal Transduct Target Ther; 2020 ; 5 8; DOI: 10.1038/s41392-020-0110-5
|
Statements
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
